Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab for Steroid-Refractory Acute Intestinal GvHD
NCT02993783Phase 2Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2017
- Primary completion
- May 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of vedolizumab in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Percentage of Participants With Overall Response (PR+VGPR+CR) at Day 28 and Number of Participants Who Experienced Serious Adverse Events at Day 28. Started Apr 2017; status: terminated.
02
Drugs
vedolizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02993783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993783.